KALV KALVISTA PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended March 31, 2026, KALVISTA PHARMACEUTICALS INC reported revenue of $40.9M, net income of −$23.5M and diluted EPS of −$0.43; for the fiscal year ended April 2025 revenue was n/a.
KALV annual revenue and earnings
- Fiscal year ended Apr 2025: revenue n/a, gross profit n/a, operating income −$188M, net income −$183M (margin n/a), EPS −$3.69
- Fiscal year ended Apr 2024: revenue $50.0M, gross profit n/a, operating income −$140M, net income −$127M (margin -253.2%), EPS −$3.44
- Fiscal year ended Apr 2023: revenue n/a, gross profit n/a, operating income −$111M, net income −$92.9M (margin n/a), EPS −$3.33
- Fiscal year ended Apr 2022: revenue n/a, gross profit n/a, operating income −$96.6M, net income −$82.3M (margin n/a), EPS −$3.36
KALV quarterly revenue and earnings
- Quarter ended Mar 31, 2026: revenue $40.9M, net income −$23.5M, EPS −$0.43
- Quarter ended Sep 30, 2025: revenue $13.7M, net income −$49.5M, EPS −$0.92
- Quarter ended Jul 31, 2025: revenue $1.40M, net income −$57.6M, EPS −$1.12
- Quarter ended Mar 31, 2025: revenue n/a, net income −$51.8M, EPS −$0.98
- Quarter ended Jan 31, 2025: revenue n/a, net income −$48.5M, EPS −$0.92
- Quarter ended Sep 30, 2024: revenue $0, net income −$39.1M, EPS −$0.84
- Quarter ended Jul 31, 2024: revenue $0, net income −$40.3M, EPS −$0.87
- Quarter ended Mar 31, 2024: revenue n/a, net income −$43.1M, EPS −$1.06
- Quarter ended Jan 31, 2024: revenue n/a, net income −$29.0M, EPS −$0.84
- Quarter ended Oct 31, 2023: revenue n/a, net income −$27.7M, EPS −$0.80
- Quarter ended Jul 31, 2023: revenue n/a, net income −$25.3M, EPS −$0.74
- Quarter ended Apr 30, 2023 (from the annual report): revenue n/a, net income −$26.3M, EPS −$0.74
- Quarter ended Jan 31, 2023: revenue n/a, net income −$21.3M, EPS −$0.75
- Quarter ended Oct 31, 2022: revenue n/a, net income −$22.3M, EPS −$0.90
- Quarter ended Jul 31, 2022: revenue n/a, net income −$23.0M, EPS −$0.94
- Quarter ended Apr 30, 2022 (from the annual report): revenue n/a, net income −$24.1M, EPS −$0.98
- Quarter ended Jan 31, 2022: revenue n/a, net income −$22.5M, EPS −$0.92
- Quarter ended Oct 31, 2021: revenue n/a, net income −$19.7M, EPS −$0.80
- Quarter ended Jul 31, 2021: revenue n/a, net income −$16.1M, EPS −$0.66
KALV cash flow, buybacks and dividends
- Fiscal year ended Apr 2025: operating cash flow −$153M, share buybacks n/a
- Fiscal year ended Apr 2024: operating cash flow −$89.2M, share buybacks n/a
- Fiscal year ended Apr 2023: operating cash flow −$75.3M, share buybacks n/a
- Fiscal year ended Apr 2022: operating cash flow −$78.1M, share buybacks n/a
KALV balance sheet
- Mar 31, 2026: cash $214M, total assets $329M, total liabilities $349M, shareholders' equity −$19.7M
- Dec 31, 2025: cash $229M, total assets $335M, total liabilities $338M, shareholders' equity −$2.71M
- Sep 30, 2025: cash $243M, total assets $340M, total liabilities $323M, shareholders' equity $17.0M
- Jul 31, 2025: cash $124M, total assets $216M, total liabilities n/a, shareholders' equity $59.4M
- Apr 30, 2025: cash $132M, total assets $251M, total liabilities $155M, shareholders' equity $117M
- Dec 31, 2024: cash $182M, total assets $295M, total liabilities $130M, shareholders' equity $164M
- Oct 31, 2024: cash $41.6M, total assets $161M, total liabilities n/a, shareholders' equity $149M
- Jul 31, 2024: cash $31.8M, total assets $200M, total liabilities n/a, shareholders' equity $181M
Is KALV profitable?
No. KALVISTA PHARMACEUTICALS INC lost $183M in its latest fiscal year.